To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

medal 2
This profile is validated by 2 label.

Company

HCS Pharma

HCS Pharma_logo
28
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

HCS PHARMA develops and markets 3D cell culture products based on its groundbreaking, exclusive and proprietary BIOMIMESYS® technology that allow to faithfully reproduce the natural microenvironment of the cells of any organ (healthy or pathologic).

Lille, Hauts-de-France, France

Send a message

English

French

English

HCS Pharma
English

French

English

HCS Pharma develops revolutionary BIOMIMESYS® extracellular matrix (ECM), a game-changing, proprietary technology for building accurate 3D cellular models that will enable a significant reduction in development time in in vitro pre-clinical drug discovery and improve the success rate to find new drugs (from 90% of failure to 90% of succcess).

Our technology faithfully reproduces the natural, 3D microenvironment of cells of any type of organ (healthy or...

See more

HCS Pharma develops revolutionary BIOMIMESYS® extracellular matrix (ECM), a game-changing, proprietary technology for building accurate 3D cellular models that will enable a significant reduction in development time in in vitro pre-clinical drug discovery and improve the success rate to find new drugs (from 90% of failure to 90% of succcess).

Our technology faithfully reproduces the natural, 3D microenvironment of cells of any type of organ (healthy or pathological). Such models will ensure better predictive results from in vitro studies, reduce the time and cost of R&D, and eliminate the need for animal testing in the pharmaceutical industry.

We succeed for the first time to:

 - keep alive and functional several weeks/months cells (such as hepatocytes) in BIOMIMESYS vs several days in 2D culture

 - recreate a functional and architectural liver organoid from iPSC differentiation in BIOMIMESYS vs immature haptocytes in 2D culture

 - recreate the mechanical stress on cancer cells due to the modification of ECM and proove that this is the mechanical stress that is the cause of the cell proliferation in a tumor.

  • 2

    Followers

  • 1

    Like

Our latest news

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
160 Entities
Angels Santé
21 Entities

Communities

Bpifrance
ADVENTURE, IT'S FRANCE! Dynamizing and making the French economy more competitive is the role of Bpifrance Entrepreneurs, welcome!
2201 Members
InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1151 Members
France Angels
France Angels est la Fédération nationale des Business Angels France Angels agit pour promouvoir les Business Angels dans les domaines économiques, sociaux et juridiques pour faire reconnaître leur utilité, leur effet positif sur l'économie et légitimer leur action.
410 Members

Our history

Start in 08/2014

  • 08/2014

    HCS Pharma founded by Nathalie MAUBON as a CRO

  • 18/12/2016

    fund raising with FINOVAM & NFA: seed

  • 07/2017

    New site with 250 m² of space with: - 2 cell culture labs - 1 automation lab with 1 robotic platform

to be continued ...